Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 869 record(s)

Req # A-2022-000959

Adverse Drug Reaction (ADR) for FLUDROCORTISONE ACETATE. Report number: E2B_05047013.

Organization: Health Canada

12 page(s)
March 2023

Req # A-2022-001103

Adverse Drug Reactions (ADRs). Report numbers: E2B_05695465, E2B_05616978, E2B_05611951, E2B_05627811, E2B_05627858, E2B_05674706, E2B_05652133, 001004932, E2B_05641696, E2B_05635869.

Organization: Health Canada

767 page(s)
March 2023

Req # A-2022-001114

Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: 000721558, 000721558, E2B_02036075, E2B_02036047, E2B_02036081, 000714891, 000720913, 000715963, 000721496, E2B_01688718.

Organization: Health Canada

111 page(s)
March 2023

Req # A-2022-001135

Adverse Drug Reaction (ADR) for DEXILANT. Report number: 001009537. ADRs for ENTYVIO. Report numbers: 001009153, 001010630, E2B_05776851, E2B_05747661, E2B_05725356, E2B_05766145. ADR for VEDOLIZUMAB. Report number: 001011002.

Organization: Health Canada

117 page(s)
March 2023

Req # A-2022-001137

Adverse Drug Reaction (ADR) for NINLARO. Report number: E2B_05754329. ADRs for IXAZOMIB. Report numbers: E2B_05765887, E2B_05775462, E2B_05769970, E2B_05769961, E2B_05769964. ADRs for ONDANSETRON. Report numbers: 001014425, 001010744, E2B_05712287, E2B_05775458.

Organization: Health Canada

224 page(s)
March 2023

Req # A-2022-001142

Adverse Drug Reaction (ADR) for VYVANSE. Report number: E2B_05734113. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_05727141, E2B_05795178, E2B_05743860, E2B_05760238. ADR for GAMMAGARD LIQUID. Report number: 001011695. ADRs for IMMUNOGLOBULIN (HUMAN). Report numbers: E2B_05726530, E2B_05792981, E2B_05726136, E2B_05747312.

Organization: Health Canada

128 page(s)
March 2023

Req # A-2022-001143

Adverse Drug Reactions (ADRs). Report numbers: E2B_05505701, E2B_05452090, E2B_05474355, E2B_05474586, E2B_05446789, E2B_05446592, E2B_05212144, E2B_05212477, E2B_02667689, 001000228.

Organization: Health Canada

232 page(s)
March 2023

Req # A-2022-001156

Adverse Drug Reactions (ADRs). Report numbers: 000999109, E2B_05075695, E2B_05494272, E2B_01976711, E2B_04454024, E2B_05053764, E2B_05280771, E2B_05427218, E2B_05453813, E2B_05474975.

Organization: Health Canada

620 page(s)
March 2023

Req # A-2022-001164

Adverse Drug Reactions (ADRs). Report numbers: E2B_05426970, E2B_05469568, E2B_01634977, 000997808, E2B_05433858, E2B_05425158, E2B_05428797, E2B_05444411, E2B_03366429, 000997986.

Organization: Health Canada

198 page(s)
March 2023

Req # A-2022-001179

Adverse Drug Reactions (ADRs). Report numbers: E2B_05763376, E2B_05796397, E2B_05794672, E2B_05777573, E2B_05759486, E2B_05756855, E2B_05746743, E2B_04309100, E2B_05723103.

Organization: Health Canada

184 page(s)
March 2023
Date modified: